Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Genmab clinical trials
The registry lists 77 studies whose lead sponsor is Genmab or one of 2 companies grouped under it. 15 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the Genmab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Genmab.
- Genmab68 studiesSame company
Something wrong?
- 6 studies →
- 3 studies →
Focus areas
Conditions Genmab leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 77. Browse all 77 →
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsRecruitingNCT03526835Phase 1/2
Sponsor listed in the registry: Merus B.V. · First submitted before Merus B.V. became part of Genmab
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)RecruitingNCT07775287Phase 3
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)RecruitingNCT05579366Phase 1/2
- Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian CancerRecruitingNCT07564141Phase 3
- A Study of GEN1106 in Participants With Solid TumorsRecruitingNCT07416123Phase 1
- First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)RecruitingNCT07384715Phase 1
- Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial CancerRecruitingNCT07166094Phase 3
- Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) CancersRecruitingNCT07539311Phase 2
- Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung CancerRecruitingNCT07288177Phase 2
- A Phase 1 Trial of GEN1119 in Participants With Solid TumorsRecruitingNCT07695831Phase 1
- An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in ChinaRecruitingNCT07604766Phase 3
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)RecruitingNCT07702032Phase 3
- Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet ChemotherapyRecruitingNCT07225270Phase 3
- Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian CancerNot yet recruitingNCT07859215Phase 3
- Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid TumorsRecruitingNCT07387068Phase 1
- Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell LymphomaTerminatedNCT05660967Phase 2
- A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)Active, not recruitingNCT06496178Phase 3
Sponsor listed in the registry: Merus B.V. · First submitted before Merus B.V. became part of Genmab
- Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid TumorsTerminatedNCT06573294Phase 1
- A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid TumorsActive, not recruitingNCT06057038Phase 1
- Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's SyndromeActive, not recruitingNCT04623541Phase 1/2
- Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)Active, not recruitingNCT04542824Phase 1/2
- Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)Active, not recruitingNCT06635824Phase 3
- First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaActive, not recruitingNCT03625037Phase 1/2
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)Active, not recruitingNCT04663347Phase 1/2
- Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)TerminatedNCT06984328Phase 2
- Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian CancerActive, not recruitingNCT06619236Phase 3
- A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Active, not recruitingNCT06525220Phase 3
Sponsor listed in the registry: Merus B.V. · First submitted before Merus B.V. became part of Genmab
- Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung CancerTerminatedNCT05117242Phase 2
- A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT05578976Phase 3
- Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of EpcoritamabActive, not recruitingNCT05206357Phase 1
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT05201248Phase 1/2
- A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular LymphomaActive, not recruitingNCT05451810Phase 2
- GEN1046 Safety Trial in Patients With Malignant Solid TumorsTerminatedNCT03917381Phase 1/2
- Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung CancerWithdrawnNCT07353957Phase 2
Sponsor listed in the registry: Merus B.V. · First submitted after Merus B.V. became part of Genmab
- A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid TumorsTerminatedNCT05491317Phase 1/2
- Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination TherapyTerminatedNCT06391775Phase 1/2
- Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular LymphomaActive, not recruitingNCT06191744Phase 3
- GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsActive, not recruitingNCT04083599Phase 1/2
- GEN1047 for Solid Tumors - First in Human (FIH) TrialTerminatedNCT05180474Phase 1/2
- A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid TumorsTerminatedNCT06685068Phase 1/2
- Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular LymphomaActive, not recruitingNCT05409066Phase 3
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaActive, not recruitingNCT05283720Phase 2
- PRO1107 in Patients With Advanced Solid TumorsTerminatedNCT06171789Phase 1/2
- A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04628494Phase 3
- GEN3014 Trial in Relapsed or Refractory Hematologic MalignanciesTerminatedNCT04824794Phase 1/2
- A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in ChinaActive, not recruitingNCT07226752Phase 3
- A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT06508658Phase 3
- Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)TerminatedNCT05721222Phase 1/2
- Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in CombinationActive, not recruitingNCT04868877Phase 1/2
Sponsor listed in the registry: Merus B.V. · First submitted before Merus B.V. became part of Genmab
- A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid TumorsTerminatedNCT06771921Phase 1/2